The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer
Human epidermal growth factor receptor 2 (HER-2) overexpressed breast cancer has traditionally been considered as an aggressive disease with high risk of systemic and brain metastases and poor prognosis. Nowadays, we have many HER-2 targeting treatments that have radically changed patients’ outcomes...
Saved in:
| Main Authors: | Larissa Russo-Vorms, Christoforos Astaras, José Sandoval, Maxime Borgeaud, Alexandre Bodmer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.09.044 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer
by: Zongbi Yi, et al.
Published: (2024-12-01) -
Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01) -
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01) -
The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024-07-01) -
In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)